FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2

The FDA has approved ZORYVE cream 0.3% for treating plaque psoriasis in children as young as age 2, marking the first once-daily, non-steroidal therapy for this indication. This is Arcutis' seventh FDA approval for ZORYVE in four years. The approval addresses a significant treatment gap for young children with plaque psoriasis, offering a steroid-free option suitable for use anywhere on the body with no duration restrictions.